These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36701109)

  • 1. Toll-Like Receptor 4 Plays a Significant Role in the Biochemical and Neurological Alterations Observed in Two Distinct Mice Models of Huntington's Disease.
    Martínez-Gopar PE; Pérez-Rodríguez MJ; Angeles-López QD; Tristán-López L; González-Espinosa C; Pérez-Severiano F
    Mol Neurobiol; 2023 May; 60(5):2678-2690. PubMed ID: 36701109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
    Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
    J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's disease.
    Bissonnette S; Vaillancourt M; Hébert SS; Drolet G; Samadi P
    PLoS One; 2013; 8(9):e75099. PubMed ID: 24040390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin.
    Damiano M; Diguet E; Malgorn C; D'Aurelio M; Galvan L; Petit F; Benhaim L; Guillermier M; Houitte D; Dufour N; Hantraye P; Canals JM; Alberch J; Delzescaux T; Déglon N; Beal MF; Brouillet E
    Hum Mol Genet; 2013 Oct; 22(19):3869-82. PubMed ID: 23720495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional Assessment of Striatal mRNAs as Valid Biomarkers of Disease Progression in Three Mouse Models of Huntington's Disease.
    Ghavami A; Olsen M; Kwan M; Beltran J; Shea J; Ramboz S; Duan W; Lavery D; Howland D; Park LC
    J Huntingtons Dis; 2020; 9(1):13-31. PubMed ID: 32007959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant Huntingtin affects toll-like receptor 4 intracellular trafficking and cytokine production in mast cells.
    Pérez-Rodríguez MJ; Ibarra-Sánchez A; Román-Figueroa A; Pérez-Severiano F; González-Espinosa C
    J Neuroinflammation; 2020 Mar; 17(1):95. PubMed ID: 32220257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
    Dufour BD; McBride JL
    Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
    MacGibbon GA; Hamilton LC; Crocker SF; Costain WJ; Murphy KM; Robertson HA; Denovan-Wright EM
    J Neurosci Res; 2002 Feb; 67(3):372-8. PubMed ID: 11813242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
    Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
    J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms.
    Farrar AM; Callahan JW; Abercrombie ED
    Exp Neurol; 2011 Dec; 232(2):119-25. PubMed ID: 21864528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
    Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
    Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The absence of the aryl hydrocarbon receptor in the R6/1 transgenic mouse model of Huntington's disease improves the neurological phenotype.
    Angeles-López QD; García-Lara L; Aguirre-Pineda N; Castañeda-Arellano R; Elizondo-Azuela G; Pérez-Severiano F; Segovia J
    Behav Brain Res; 2021 Jun; 408():113230. PubMed ID: 33684424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
    Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
    Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
    Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
    Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IKKβ slows Huntington's disease progression in R6/1 mice.
    Ochaba J; Fote G; Kachemov M; Thein S; Yeung SY; Lau AL; Hernandez S; Lim RG; Casale M; Neel MJ; Monuki ES; Reidling J; Housman DE; Thompson LM; Steffan JS
    Proc Natl Acad Sci U S A; 2019 May; 116(22):10952-10961. PubMed ID: 31088970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice.
    Dickson E; Soylu-Kucharz R; Petersén Å; Björkqvist M
    Mol Metab; 2022 Mar; 57():101439. PubMed ID: 35007790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.